Mereo BioPharma Group plc (NASDAQ: MREO) is 61.33% higher on its value in year-to-date trading and has touched a low of $0.43 and a high of $1.85 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The MREO stock was last observed hovering at around $1.28 in the last trading session, with the day’s loss setting it -0.07% off its average median price target of $4.00 for the next 12 months. It is also 75.8% off the consensus price target high of $5.00 offered by 4 analysts, but current levels are 69.75% higher than the price target low of $4.00 for the same period.
Currently trading at $1.21, the stock is -0.90% and 18.92% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.82 million and changing -5.47% at the moment leaves the stock 26.99% off its SMA200. MREO registered 127.06% gain for a year compared to 6-month gain of 63.51%. The firm has a 200-day simple moving average (SMA200) of -$1.98.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
The stock witnessed a 16.35% loss in the last 1 month and extending the period to 3 months gives it a 25.09%, and is 5.22% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 13.82% over the week and 11.26% over the month.
Distance from 52-week low is 180.68% and -34.59% from its 52-week high.
Mereo BioPharma Group plc (MREO) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Mereo BioPharma Group plc (MREO) is a “Buy”. 4 analysts offering their recommendations for the stock have an average rating of 1.70, where 0 rate it as a Hold and 0 think it is a “Overweight”. 4 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Mereo BioPharma Group plc is expected to release its quarterly report on 08/09/2023.
Mereo BioPharma Group plc (MREO) Top Institutional Holders
The shares outstanding are 124.99M, and float is at 124.99M with Short Float at 3.38%.